Health
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one participant achieving a tumor reduction of approximately 79%. – Additionally, three participants, including one individual with three prior lines of treatment, achieved stable disease at lower dose cohorts, with tumor size reductions ranging between 24% to 2
About this update from Genelux Corporation
[{"type":"image","alt":"Genelux Corporation","displaySize":"","headline":null,"caption":"Genelux Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/555a19f80dbf3a9d98dbd557739b10ea"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PqbnzpB7NuWaPPuiKZD5BA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/555a19f80dbf3a9d98dbd557739b10ea","width":300,"height":75}},"lazy":false},{"type":"text","content":"– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one participant achieving a tumor reduction of approximately 79%.","length":309,"tagName":"p"},{"type":"text","content":"– Additionally, three participants, including one individual with three prior lines of treatment, achieved stable disease at lower dose cohorts, with tumor size reductions ranging between 24% to 29.2%.","length":207,"tagName":"p"},{"type":"text","content":"– Data are supportive of Olvi-Vec being a platinum resensitizing agent beyond ovarian cancer and, consistent with earlier studies, being systemically administered in multiple solid tumor types which underscore the current clinical development strategy.","length":258,"tagName":"p"},{"type":"text","content":"– Olvi-Vec was generally well-tolerated with a favorable safety profile. Participant enrollment into dose escalation cohorts continues to investigate safety and the recommended intravenous dose of Olvi-Vec for the Phase 2 trial.","length":239,"tagName":"p"},{"type":"text","content":"WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, and Newsoara BioPharma Co., Ltd., a pre-commercial-stage biopharmaceutical company, today announced preliminary safety and anti-tumor activity data from the dose escalation Phase 1b portion of the companies’ co-sponsored ongoing Phase 1b/2 clinical trial (OLVI-VEC-SCLC-202) of Olvi-Vec immunochemotherapy in patients with platinum-relapsed or platinum-refractory extensive small cell lung cancer.","length":541,"tagName":"p"},{"type":"text","content":"“We are ...